SB253 (2025) Compare Changes


The Bill Text indicates a new section is being inserted. This situation is not handled right now, and the new text is displayed in both the changed and unchanged versions.

Unchanged Version

Text to be removed highlighted in red.

1 New Paragraph; Trade and Commerce; Regulation of Business Practices for Consumer Protection. Amend RSA 358-A:2 by inserting after paragraph XIX the following new paragraph:

XX. A drug manufacturer under RSA 318, an agent or affiliate of such manufacturer, or a distributor or third-party logistics provider of such manufacturer's drugs, directly or indirectly:

(a) Denying, restricting, or prohibiting the acquisition of a 340B covered drug, as defined in 42 U.S.C. section 256b et seq., by, or delivery of a 340B covered drug to, any location authorized by a 340B covered entity, as defined in 42 U.S.C. section 256b et seq., to receive such 340B covered drug, unless receipt of the 340B covered drug is prohibited by federal law; and/or

(b) Requiring a 340B covered entity to submit any claims or utilization data as a condition for allowing the acquisition of a 340B covered drug by, or delivery of a 340B covered drug to, a 340B covered entity unless the claims or utilization data sharing is required by federal law.

2 Effective Date. This act shall take effect January 1, 2026.

Changed Version

Text to be added highlighted in green.

1 New Paragraph; Trade and Commerce; Regulation of Business Practices for Consumer Protection. Amend RSA 358-A:2 by inserting after paragraph XIX the following new paragraph:

XX. A drug manufacturer under RSA 318, an agent or affiliate of such manufacturer, or a distributor or third-party logistics provider of such manufacturer's drugs, directly or indirectly:

(a) Denying, restricting, or prohibiting the acquisition of a 340B covered drug, as defined in 42 U.S.C. section 256b et seq., by, or delivery of a 340B covered drug to, any location authorized by a 340B covered entity, as defined in 42 U.S.C. section 256b et seq., to receive such 340B covered drug, unless receipt of the 340B covered drug is prohibited by federal law; and/or

(b) Requiring a 340B covered entity to submit any claims or utilization data as a condition for allowing the acquisition of a 340B covered drug by, or delivery of a 340B covered drug to, a 340B covered entity unless the claims or utilization data sharing is required by federal law.

2 Effective Date. This act shall take effect January 1, 2026.